Literature DB >> 31549359

A Need for Change! A Coding Framework for Improving Transparency in Decision Modeling.

Fernando Alarid-Escudero1, Eline M Krijkamp2, Petros Pechlivanoglou3, Hawre Jalal4, Szu-Yu Zoe Kao5, Alan Yang6, Eva A Enns5.   

Abstract

The use of open-source programming languages, such as R, in health decision sciences is growing and has the potential to facilitate model transparency, reproducibility, and shareability. However, realizing this potential can be challenging. Models are complex and primarily built to answer a research question, with model sharing and transparency relegated to being secondary goals. Consequently, code is often neither well documented nor systematically organized in a comprehensible and shareable approach. Moreover, many decision modelers are not formally trained in computer programming and may lack good coding practices, further compounding the problem of model transparency. To address these challenges, we propose a high-level framework for model-based decision and cost-effectiveness analyses (CEA) in R. The proposed framework consists of a conceptual, modular structure and coding recommendations for the implementation of model-based decision analyses in R. This framework defines a set of common decision model elements divided into five components: (1) model inputs, (2) decision model implementation, (3) model calibration, (4) model validation, and (5) analysis. The first four components form the model development phase. The analysis component is the application of the fully developed decision model to answer the policy or the research question of interest, assess decision uncertainty, and/or to determine the value of future research through value of information (VOI) analysis. In this framework, we also make recommendations for good coding practices specific to decision modeling, such as file organization and variable naming conventions. We showcase the framework through a fully functional, testbed decision model, which is hosted on GitHub for free download and easy adaptation to other applications. The use of this framework in decision modeling will improve code readability and model sharing, paving the way to an ideal, open-source world.

Entities:  

Year:  2019        PMID: 31549359      PMCID: PMC6871515          DOI: 10.1007/s40273-019-00837-x

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  18 in total

Review 1.  Empirically evaluating decision-analytic models.

Authors:  Jeremy D Goldhaber-Fiebert; Natasha K Stout; Sue J Goldie
Journal:  Value Health       Date:  2010-03-10       Impact factor: 5.725

Review 2.  Calibration methods used in cancer simulation models and suggested reporting guidelines.

Authors:  Natasha K Stout; Amy B Knudsen; Chung Yin Kong; Pamela M McMahon; G Scott Gazelle
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

3.  The Curve of Optimal Sample Size (COSS): A Graphical Representation of the Optimal Sample Size from a Value of Information Analysis.

Authors:  Eric Jutkowitz; Fernando Alarid-Escudero; Karen M Kuntz; Hawre Jalal
Journal:  Pharmacoeconomics       Date:  2019-07       Impact factor: 4.981

4.  Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6.

Authors:  Andrew H Briggs; Milton C Weinstein; Elisabeth A L Fenwick; Jonathan Karnon; Mark J Sculpher; A David Paltiel
Journal:  Med Decis Making       Date:  2012 Sep-Oct       Impact factor: 2.583

5.  A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis.

Authors:  Devin Incerti; Jeffrey R Curtis; Jason Shafrin; Darius N Lakdawalla; Jeroen P Jansen
Journal:  Pharmacoeconomics       Date:  2019-06       Impact factor: 4.981

Review 6.  Transparency in Decision Modelling: What, Why, Who and How?

Authors:  Christopher James Sampson; Renée Arnold; Stirling Bryan; Philip Clarke; Sean Ekins; Anthony Hatswell; Neil Hawkins; Sue Langham; Deborah Marshall; Mohsen Sadatsafavi; Will Sullivan; Edward C F Wilson; Tim Wrightson
Journal:  Pharmacoeconomics       Date:  2019-11       Impact factor: 4.981

7.  Nonidentifiability in Model Calibration and Implications for Medical Decision Making.

Authors:  Fernando Alarid-Escudero; Richard F MacLehose; Yadira Peralta; Karen M Kuntz; Eva A Enns
Journal:  Med Decis Making       Date:  2018-10       Impact factor: 2.583

8.  Model Registration: A Call to Action.

Authors:  Christopher James Sampson; Tim Wrightson
Journal:  Pharmacoecon Open       Date:  2017-06

9.  Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors.

Authors:  Darren B Taichman; Peush Sahni; Anja Pinborg; Larry Peiperl; Christine Laine; Astrid James; Sung-Tae Hong; Abraham Haileamlak; Laragh Gollogly; Fiona Godlee; Frank A Frizelle; Fernando Florenzano; Jeffrey M Drazen; Howard Bauchner; Christopher Baethge; Joyce Backus
Journal:  PLoS Med       Date:  2017-06-05       Impact factor: 11.069

10.  Benefits, Challenges and Potential Strategies of Open Source Health Economic Models.

Authors:  William C N Dunlop; Nicola Mason; James Kenworthy; Ron L Akehurst
Journal:  Pharmacoeconomics       Date:  2017-01       Impact factor: 4.981

View more
  9 in total

1.  Dissemination Science to Advance the Use of Simulation Modeling: Our Obligation Moving Forward.

Authors:  Bohdan Nosyk; Janet Weiner; Emanuel Krebs; Xiao Zang; Benjamin Enns; Czarina N Behrends; Daniel J Feaster; Hawre Jalal; Brandon D L Marshall; Ankur Pandya; Bruce R Schackman; Zachary F Meisel
Journal:  Med Decis Making       Date:  2020-08-05       Impact factor: 2.583

2.  Improving Transparency in Decision Models: Current Issues and Potential Solutions.

Authors:  Paul Tappenden; J Jaime Caro
Journal:  Pharmacoeconomics       Date:  2019-11       Impact factor: 4.981

3.  CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness Analysis.

Authors:  Fernando Alarid-Escudero; Deborah Schrag; Karen M Kuntz
Journal:  Value Health       Date:  2021-11-02       Impact factor: 5.725

4.  Cost-effectiveness of direct surgery versus preoperative octreotide therapy for growth-hormone secreting pituitary adenomas.

Authors:  Shaun J Kilty; Myriam G M Hunink; Lisa Caulley; Eline Krijkamp; Mary-Anne Doyle; Kednapa Thavorn; Fahad Alkherayf; Nick Sahlollbey; Selina X Dong; Jason Quinn; Stephanie Johnson-Obaseki; David Schramm
Journal:  Pituitary       Date:  2022-08-27       Impact factor: 3.599

5.  Minimizing Population Health Loss in Times of Scarce Surgical Capacity During the Coronavirus Disease 2019 Crisis and Beyond: A Modeling Study.

Authors:  Benjamin Gravesteijn; Eline Krijkamp; Jan Busschbach; Geert Geleijnse; Isabel Retel Helmrich; Sophie Bruinsma; Céline van Lint; Ernest van Veen; Ewout Steyerberg; Kees Verhoef; Jan van Saase; Hester Lingsma; Rob Baatenburg de Jong
Journal:  Value Health       Date:  2021-03-05       Impact factor: 5.725

6.  Exploring the drivers and barriers to uptake for digital contact tracing.

Authors:  Andrew Tzer-Yeu Chen; Kimberly Widia Thio
Journal:  Soc Sci Humanit Open       Date:  2021-10-07

7.  Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials.

Authors:  Stijntje W Dijk; Eline M Krijkamp; Natalia Kunst; Cary P Gross; John B Wong; M G Myriam Hunink
Journal:  Value Health       Date:  2022-04-28       Impact factor: 5.101

8.  Simulation models of sugary drink policies: A scoping review.

Authors:  Natalie Riva Smith; Anna H Grummon; Shu Wen Ng; Sarah Towner Wright; Leah Frerichs
Journal:  PLoS One       Date:  2022-10-03       Impact factor: 3.752

Review 9.  Evolution and Reproducibility of Simulation Modeling in Epidemiology and Health Policy Over Half a Century.

Authors:  Mohammad S Jalali; Catherine DiGennaro; Abby Guitar; Karen Lew; Hazhir Rahmandad
Journal:  Epidemiol Rev       Date:  2022-01-14       Impact factor: 6.222

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.